Pregabalin and injury: A nested case-control and case-crossover study.
case-control
case-crossover
fracture
injury
pharmacoepidemiology
pregabalin
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
10
09
2019
revised:
21
01
2020
accepted:
03
02
2020
pubmed:
23
2
2020
medline:
10
4
2021
entrez:
23
2
2020
Statut:
ppublish
Résumé
This study was performed to investigate the association between the use of pregabalin and injury. The study was based on a predefined cohort of patients aged ≥20 years who had been registered for ≥6 months and contributed to the Japan Medical Data Center claims database. All patients (cases) had been treated for injuries from January 2014 to December 2016. One-to-four case-control matching was performed for age, sex, calendar day of injury (index date), and follow-up duration. A conditional logistic regression analysis was performed to calculate the odds ratio (OR) for pregabalin use within 180 days prior to the index date between the matched cases and controls, with adjustment for comorbidities and relevant drug categories associated with a risk of injury. To minimize within-individual confounding, we also performed a case-crossover analysis to compare the odds of pregabalin use between a 30-day hazard period immediately before the injury and five consecutive 30-day control periods within individuals with injury. Among the 2 324 974 people in the nested cohort, we identified 18 084 cases with injury and 71 885 matched controls. The proportion of pregabalin use was 1.7% (304/18 084) and 1.1% (803/71 885), respectively. The adjusted OR for injury was 1.22 (95% confidence interval [CI], 1.06-1.40). In the case-crossover analysis (n = 304), pregabalin use was also significantly associated with an increased risk of injury (adjusted OR, 1.48; 95% CI, 1.10-2.00). This large database study using two different study designs consistently suggested that the use of pregabalin may be associated with an increased risk of injury.
Substances chimiques
Analgesics
0
Pregabalin
55JG375S6M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
558-564Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654-662. https://doi.org/10.1016/j.pain.2013.11.013.
Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328-335. https://doi.org/10.1155/2014/754693.
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-173. https://doi.org/10.1016/S1474-4422(14)70251-0.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88. https://doi.org/10.1111/j.1468-1331.2010.02999.x.
Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA. 2018;320:2149-2151. https://doi.org/10.1001/jama.2018.12358.
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179:695-701. https://doi.org/10.1001/jamainternmed.2019.0086.
Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178:292-294. https://doi.org/10.1001/jamainternmed.2017.7856.
Hirakata M, Yoshida S, Tanaka-Mizuno S, Kuwauchi A, Kawakami K. Pregabalin prescription for neuropathic pain and fibromyalgia: a descriptive study using administrative database in Japan. Pain Res Manag. 2018;2018:1-10. https://doi.org/10.1155/2018/2786151.
Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010;11:85. https://doi.org/10.1186/1471-2296-11-85.
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076. https://doi.org/10.1002/14651858.CD007076.pub3.
Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019;9:e023600. https://doi.org/10.1136/bmjopen-2018-023600.
Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014;5:38-56. https://doi.org/10.1177/2042098613505614.
Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169:732-734. https://doi.org/10.7326/M18-1136.
Molero Y, Larsson H, D'Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019;365:l2147. https://doi.org/10.1136/bmj.l2147.
Ho JM-W, Macdonald EM, Luo J, et al. Pregabalin and heart failure: a population-based study. Pharmacoepidemiol Drug Saf. 2017;26:1087-1092. https://doi.org/10.1002/pds.4239.
Mukai R, Hasegawa S, Umetsu R, et al. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese adverse drug event report databases. J Clin Pharm Ther. 2018;44:285-291. https://doi.org/10.1111/jcpt.12790.
Vandenbroucke JP, Pearce N. Case-control studies: basic concepts. Int J Epidemiol. 2012;41:1480-1489. https://doi.org/10.1093/ije/dys147.
Nyström H, Nordström A, Nordström P. Risk of injurious fall and hip fracture up to 26 y before the diagnosis of Parkinson disease: nested case-control studies in a nationwide cohort. PLoS Med. 2016;13:e1001954. https://doi.org/10.1371/journal.pmed.1001954.
Modén B, Merlo J, Ohlsson H, Rosvall M. Psychotropic drugs and falling accidents among the elderly: a nested case control study in the whole population of Scania, Sweden. J Epidemiol Community Health. 2010;64:440-446. https://doi.org/10.1136/jech.2009.098947.
Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952-1960. https://doi.org/10.1001/archinternmed.2009.357.
Morin L, Calderon Larrañaga A, Welmer A-K, Rizzuto D, Wastesson JW, Johnell K. Polypharmacy and injurious falls in older adults: a nationwide nested case-control study. Clin Epidemiol. 2019;11:483-493. https://doi.org/10.2147/CLEP.S201614.
Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676-682. https://doi.org/10.1093/aje/kwq433.
Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat. Simul Comput. 2009;38:1228-1234. https://doi.org/10.1080/03610910902859574.
Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144-153. https://doi.org/10.1093/oxfordjournals.aje.a115853.
Mittleman MA, Mostofsky E. Exchangeability in the case-crossover design. Int J Epidemiol. 2014;43:1645-1655. https://doi.org/10.1093/ije/dyu081.
R: The R Project for Statistical Computing. https://www.r-project.org/. Accessed January 3, 2020.
Chimirri S, Aiello R, Mazzitello C, et al. Vertigo/dizziness as a drugs' adverse reaction. J Pharmacol Pharmacother. 2013;4:S104-S109. https://doi.org/10.4103/0976-500X.120969.
Alyono JC. Vertigo and dizziness: understanding and managing fall risk. Otolaryngol Clin North Am. 2018;51:725-740. https://doi.org/10.1016/j.otc.2018.03.003.
Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol. 2018;29:1970-1978. https://doi.org/10.1681/ASN.2018010096.